Researchers believe that combination therapy may be required for specific tumor types and that other drugs should be added to PD-1/PD-L1 inhibitors to improve the response rate, produce a lasting response, and thus achieve a better outcome [9]. The gene discussed is PDCD1; the disease is neoplasm.